Biosafety Issues in Lentivector Production

  • C. Delenda
  • M. Audit
  • O. Danos
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 261)


The development of efficient lentivectors brings about exciting possibilities for novel therapeutic interventions. Still, as new biologicals intended to be used in the clinic, these vectors will have to comply with a complete set of requirements regarding their mode of preparation and characterization. Over the past 50 years, there has been an increasing awareness of the safety issues surrounding the manufacturing of medicinal products. Regulatory authorities and agencies regularly publish guidelines and coordinate international conferences on harmonization (ICH), whose goal is to define common standards for biotechnological and biological products to be administered to human patients (SCHULTZ 1998).


Ciency Virus Rous Sarcoma Virus Packaging System Human Immunode Gene Transfer Vector 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adkins B, Hunter T (1981) Identification of a packaged cellular mRNA in virions of rous sarcoma virus. J Virol 39:471–480PubMedGoogle Scholar
  2. Aiken C (1997) Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 71:5871–5877PubMedGoogle Scholar
  3. Andreadis S, Palsson BO (1997) Coupled effects of polybrene and calf serum on the efficiency of retroviral transduction and the stability of retroviral vectors. Hum Gene Ther 8:285–291PubMedCrossRefGoogle Scholar
  4. Aronoff R, Linial M (1991) Specificity of retroviral RNA packaging. J Virol 65:71–80PubMedGoogle Scholar
  5. Arthur LO, Bess JW Jr, Sowder RCd, Benveniste RE, Mann DL, Chermann JC, Henderson LE (1992) Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines [see comments]. Science 258:1935–1938PubMedCrossRefGoogle Scholar
  6. Berglund JA, Charpentier B, Rosbash M (1997) A high affinity binding site for the HIV-1 nucleocapsid protein. Nucleic Acids Res 25:1042–1049PubMedCrossRefGoogle Scholar
  7. Berkhout B, van Wamel J, Klaver B (1995) Requirements for DNA strand transfer during reverse transcription in mutant HIV-1 virions. J Mol Biol 252:59–69PubMedCrossRefGoogle Scholar
  8. Bess JW Jr, Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO (1997) Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 230:134–144PubMedCrossRefGoogle Scholar
  9. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH (1997) Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 71:6641–6649PubMedGoogle Scholar
  10. Braaten D, Franke EK, Luban J (1996) Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J Virol 70:4220–4227PubMedGoogle Scholar
  11. Bukrinsky M, Adzhubei A (1999) Vial protein R of HIV-1. Rev Med Virol 9:39–49PubMedCrossRefGoogle Scholar
  12. Callahan MA, Handley MA, Lee YH, Talbot KJ, Harper JW, Panganiban AT (1998) Functional interaction of human immunodeficiency virus type 1 Vpu and Gag with a novel member of the tetratricopeptide repeat protein family. J Virol 72:8461PubMedGoogle Scholar
  13. Cantin R, Fortin JF, Tremblay M (1996) The amount of host HLA-DR proteins acquired by HIV-1 is virus strain-and cell type-specific. Virology 218:372–381PubMedCrossRefGoogle Scholar
  14. Capobianchi MR, Fais S, Castilletti C, Gentile M, Ameglio F, Dianzani F (1994) A simple and reliable method to detect cell membrane proteins on infectious human immunodeficiency virus type 1 particles. J Infect Dis 169:886–889PubMedCrossRefGoogle Scholar
  15. Castilletti C, Capobianchi MR, Fais S, Abbate I, Ficociello B, Ameglio F, Cordiali Fei P, Santini SM, Dianzani F (1995) HIV type 1 grown on interferon gamma-treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA-DR and enhanced infectivity for CD4-negative cells. AIDS Res Hum Retroviruses 11:547–553PubMedCrossRefGoogle Scholar
  16. Chang LJ, Urlacher V, Iwakuma T, Cui Y, Zucali J (1999) Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther 6:715–728PubMedCrossRefGoogle Scholar
  17. Chinnasamy D, Chinnasamy N, Enriquez M, Otsu M, Morgan R, Candotti F (2000) Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 96:1309–1316PubMedGoogle Scholar
  18. Cimarelli A, Luban J (1999) Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol 73:5388–5401PubMedGoogle Scholar
  19. Clavel F, Chameau P (1994) Fusion from without directed by human immunodeficiency virus particles. J Virol 68:1179–1185PubMedGoogle Scholar
  20. Clever JL, Taplitz RA, Lochrie MA, Polisky B, Parslow TG (2000) A heterologous, high-affinity RNA ligand for human immunodeficiency virus Gag protein has RNA packaging activity. J Virol 74: 541–546PubMedCrossRefGoogle Scholar
  21. Cone R, Reilly E, Eisen H, Mulligan R (1987) Tissue-specific expression of functionally rearranged lamda 1 Ig gene through a retrovirus vector. Science 236:954–957PubMedCrossRefGoogle Scholar
  22. Danos O, Mulligan RC (1988) Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85:6460–6464PubMedCrossRefGoogle Scholar
  23. Delviks K, Hu W, Pathak V (1997) Ψ-vectors: murine leukemia virus-based self-inactivating and self activating retroviral vectors. J Virol 71:6218–6224PubMedGoogle Scholar
  24. Donahue RE, Kessler SW, Bodine D, McDonagh K, Dunbar C, Goodman S, Agricola B, Byrne E, Raffeld M, Moen R et al. (1992) Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 176:1125–1135PubMedCrossRefGoogle Scholar
  25. Duisit G, Salvetti A, Moullier P, Cosset FL (1999) Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum Gene Ther 10:189–200PubMedCrossRefGoogle Scholar
  26. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463–8471PubMedGoogle Scholar
  27. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25:217–222PubMedCrossRefGoogle Scholar
  28. Frank I, Stoiber H, Godar S, Stockinger H, Steindl F, Katinger HW, Dierich MP (1996) Acquisition of host cell-surface-derived molecules by HIV-1. Aids 10:1611–1620PubMedCrossRefGoogle Scholar
  29. Gallichan WS, Kafri T, Krahl T, Verma IM, Sarvetnick N (1998) Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum Gene Ther 9:2717–2726PubMedCrossRefGoogle Scholar
  30. Gasmi M, Glynn J, Jin MJ, Jolly DJ, Yee JK, Chen ST (1999) Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J Virol 73:1828–1834PubMedGoogle Scholar
  31. Han JJ, Mhatre AN, Wareing M, Pettis R, Gao WQ, Zufferey RN, Trono D, Lalwani AK (1999) Transgene expression in the guinea pig cochlea mediated by a lentivirus-derived gene transfer vector. Hum Gene Ther 10:1867–1873PubMedCrossRefGoogle Scholar
  32. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P (1998) Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95:163–175PubMedCrossRefGoogle Scholar
  33. Holzer GW, Mayrhofer JA, Gritschenberger W, Dorner F, Falkner FG (1999) Poxviral/retroviral chimeric vectors allow cytoplasmic production of transducing defective retroviral particles. Virology 253:107–114PubMedCrossRefGoogle Scholar
  34. Hu WS, Temin HM (1990) Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination. Proc Natl Acad Sci USA 87:1556–1560PubMedCrossRefGoogle Scholar
  35. Ikawa Y, Ross J, Leder P (1974) An association between globin messenger RNA and 60S RNA derived from Friend leukemia virus. Proc Natl Acad Sci USA 71:1154–1158PubMedCrossRefGoogle Scholar
  36. Iwakuma T, Cui Y, Chang LJ (1999) Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 261:120–132PubMedCrossRefGoogle Scholar
  37. Jacque JM, Mann A, Enslen H, Sharova N, Brichacek B, Davis RJ, Stevenson M (1998) Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase. Embo J 17:2607–2618PubMedCrossRefGoogle Scholar
  38. Johnston J, Power C (1999) Productive infection of human peripheral blood mononuclear cells by feline immunodeficiency virus: implications for vector development. J Virol 73:2491–2498PubMedGoogle Scholar
  39. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM (1997) Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 17:314–317PubMedCrossRefGoogle Scholar
  40. Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM (1999) A packaging cell line for lentivirus vectors. J Virol 73:576–584PubMedGoogle Scholar
  41. Kaplan AH, Swanstrom R (1991) The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity. Biomed Biochim Acta 50:647–653PubMedGoogle Scholar
  42. Kaul M, Yu H, Ron Y, Dougherty JP (1998) Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences. Virology 249:167–174PubMedCrossRefGoogle Scholar
  43. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ (1998) Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 72:811–816PubMedGoogle Scholar
  44. Kimpton J, Emerman M (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 66:2232–2239PubMedGoogle Scholar
  45. Klages N, Zufferey R, Trono D (2000) A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther 2:170–176PubMedCrossRefGoogle Scholar
  46. Kordower JH, Bloch J, Ma SY, Chu Y, Palfl S, Roitberg BZ, Emborg M, Hantraye P, Deglon N, Aebischer P (1999) Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 160:1–16PubMedCrossRefGoogle Scholar
  47. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA (2000) A Rev-independent human immunodeficiency virus type 1 (HlV-l)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 74:4839–4852PubMedCrossRefGoogle Scholar
  48. Lama J, Trono D (1998) Human immunodeficiency virus type 1 matrix protein interacts with cellular protein HO3. J Virol 72:1671–1676PubMedGoogle Scholar
  49. Mangeot PE, NEgre D, Dubois B, Winter AJ, Leissner P, Mehtali M, Kaiserlian D, Cosset FL, Darlix JL (2000) Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J Virol 74:8307–8315PubMedCrossRefGoogle Scholar
  50. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH et al. (1994) Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:1587–1590PubMedCrossRefGoogle Scholar
  51. Mautino MR, Keiser N, Morgan RA (2000a) Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element. Gene Ther 7:1421–1424PubMedCrossRefGoogle Scholar
  52. Mautino MR, Ramsey WJ, Reiser J, Morgan RA (2000b) Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev. Hum Gene Ther 11:895–908PubMedCrossRefGoogle Scholar
  53. Metharom P, Takyar S, Xia HH, Ellem KA, Macmillan J, Shepherd RW, Wilcox GE, Wei MQ (2000) Novel bovine lentiviral vectors based on Jembrana disease virus. J Gene Med 2:176–185PubMedCrossRefGoogle Scholar
  54. Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, Kim V, Kingsman S, Kingsman A, Mazarakis N (1999) Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 6:1808–1818PubMedCrossRefGoogle Scholar
  55. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998) Development of a self-inactivating lentivirus vector. J Virol 72:8150–8157PubMedGoogle Scholar
  56. Miyoshi H, Takahashi M, Gage FH, Verma IM (1997) Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 94:10319–10323PubMedCrossRefGoogle Scholar
  57. Mochizuki H, Schwartz JP, Tanaka K, Brady RO, Reiser J (1998) High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol 72:8873–8883PubMedGoogle Scholar
  58. Mouland AJ, Mercier J, Luo M, Bernier L, DesGroseillers L, Cohen EA (2000) The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: evidence for a role in genomic RNA encapsidation. J Virol 74:5441–5451PubMedCrossRefGoogle Scholar
  59. Mselli-Lakhal L, Favier C, Da Silva Teixeira MF, Chettab K, Legras C, Ronfort C, Verdier G, Mornex JF, Chebloune Y (1998) Defective RNA packaging is responsible for low transduction efficiency of CAEV-based vectors. Arch Virol 143:681–695PubMedCrossRefGoogle Scholar
  60. Naldini L, Blomer U, Gage FH, Trono D, Verma IM (1996a) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 93:11382–11388PubMedCrossRefGoogle Scholar
  61. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996b) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267PubMedCrossRefGoogle Scholar
  62. Ott DE, Coren LV, Copeland TD, Kane BP, Johnson DG, Sowder RC II, Yoshinaka Y, Oroszlan S, Arthur LO, Henderson LE (1998) Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus. J Virol 72:2962–2968PubMedGoogle Scholar
  63. Ott DE, Coren LV, Kane BP, Busch LK, Johnson DG, Sowder RC II, Chertova EN, Arthur LO, Henderson LE (1996) Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. J Virol 70:7734–7743PubMedGoogle Scholar
  64. Page KA, Landau NR, Littman DR (1990) Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol 64:5270–5276PubMedGoogle Scholar
  65. Park F, Ohashi K, Chiu W, Naldini L, Kay MA (2000) Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat Genet 24:49–52PubMedCrossRefGoogle Scholar
  66. Piguet V, Schwartz O, Le Gall S, Trono D (1999) The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol Rev 168: 51–63PubMedCrossRefGoogle Scholar
  67. Poeschla E, Gilbert J, Li X, Huang S, Ho A, Wong-Staal F (1998a) Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors. J Virol 72:6527–6536PubMedGoogle Scholar
  68. Poeschla EM, Wong-Staal F, Looney DJ (1998b) Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 4:354–357PubMedCrossRefGoogle Scholar
  69. Putkonen P, Walther L, Zhang YJ, Li SL, Nilsson C, Albert J, Biberfeld P, Thorstensson R, Biberfeld G (1995) Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nat Med 1:914–918PubMedCrossRefGoogle Scholar
  70. Razin S, Yogev D, Naot Y (1998) Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 62:1094–1156PubMedGoogle Scholar
  71. Reiser J (2000) Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 7:910–913Google Scholar
  72. Rey O, Canon J, Krogstad P (1996) HIV-1 Gag protein associates with F-actin present in microfilaments. Virology 220:530–534PubMedCrossRefGoogle Scholar
  73. Rolls M, Webster P, Balba N, Rose J (1994) Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA. Cell 79:497–506PubMedCrossRefGoogle Scholar
  74. Russell DW, Miller AD (1996) Foamy virus vectors. J Virol 70:217–222PubMedGoogle Scholar
  75. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT (1995) Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 182:501–509PubMedCrossRefGoogle Scholar
  76. Saphire AC, Bobardt MD, Gallay PA (1999) Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. Embo J 18:6771–6785PubMedCrossRefGoogle Scholar
  77. Savard N, Cosset FL, Epstein AL (1997) Defective herpes simplex virus type 1 vectors harboring gag, pol, and env genes can be used to rescue defective retrovirus vectors. J Virol 71:4111–4117PubMedGoogle Scholar
  78. Schnell T, Foley P, Wirth M, Munch J, Uberla K (2000) Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 11:439–447PubMedCrossRefGoogle Scholar
  79. Schultz WB (1998) International conference on harmonization; guidance on quality of biotechnological/ biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Fed Regist 63:50244–50249Google Scholar
  80. Srinivasakumar N, Schuening FG (1999) A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery. J Virol 73:9589–9598PubMedGoogle Scholar
  81. Stitz J, Buchholz CJ, Engelstadter M, Uckert W, Bloemer U, Schmitt I, Cichutek K (2000) Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 273:16–20PubMedCrossRefGoogle Scholar
  82. Swain A, Coffin JM (1992) Mechanism of transduction by retroviruses. Science 255:841–845PubMedCrossRefGoogle Scholar
  83. Takahashi M, Miyoshi H, Verma IM, Gage FH (1999) Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J Virol 73:7812–7816PubMedGoogle Scholar
  84. Uphoff CC, Drexler HG (1999) Detection of mycoplasma contaminations in cell cultures by PCR analysis. Hum Cell 12:229–236PubMedGoogle Scholar
  85. van der Laan L, Lockey C, Griffeth B, Frasier F, Wilson C, Onions D, Hering B, Long Z, Otto E, Torbett B, Salomon D (2000) Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice. Nature 407:90–94PubMedCrossRefGoogle Scholar
  86. Wagner R, Graf M, Bieler K, Wolf H, Grunwald T, Foley P, Uberla K (2000) Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 11: 2403–2413PubMedCrossRefGoogle Scholar
  87. Wahlfors JJ, Xanthopoulos KG, Morgan RA (1997) Semliki Forest virus-mediated production of retroviral vector RNA in retroviral packaging cells. Hum Gene Ther 8:2031–2041PubMedCrossRefGoogle Scholar
  88. Wilson C, Ng T, Miller A (1997) Evaluation of recommandations for replication competent retrovirus testing associated with use of retroviral vectors. Hum Gene Ther 8:869–874PubMedCrossRefGoogle Scholar
  89. Wu X, Wakefleld JK, Liu H, Xiao H, Kralovics R, Prchal JT, Kappes JC (2000) Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther 2:47–55PubMedCrossRefGoogle Scholar
  90. Yang J, Bogerd H, Peng S, Wiegand H, Truant R, Cullen B (1999) An ancient family of human endogenous retro viruses encodes a functional homolog of the HIV-1 Rev protein. Proc Natl Acad Sci USA 96:13404–13408PubMedCrossRefGoogle Scholar
  91. Yu H, Rabson AB, Kaul M, Ron Y, Dougherty JP (1996) Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol 70:4530–7453PubMedGoogle Scholar
  92. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Chameau P (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173–185PubMedCrossRefGoogle Scholar
  93. Zhang QY, Clausen PA, Yatsula BA, Calothy G, Blair DG (1998) Mutation of polyadenylation signals generates murine retroviruses that produce fused virus-cell RNA transcripts at high frequency. Virology 241:80–93PubMedCrossRefGoogle Scholar
  94. Zufferey R, Donello JE, Trono D, Hope TJ (1999) Woodchuck hepatitis virus post-transcriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73: 2886–2892PubMedGoogle Scholar
  95. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873–9880PubMedGoogle Scholar
  96. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15:871–875PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • C. Delenda
    • 1
  • M. Audit
    • 1
  • O. Danos
    • 1
  1. 1.Genethon IIIEvry Cedex 02France

Personalised recommendations